- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
A new report on Tuberculosis (TB) released on 22 October by the World Health Organization shows that 9 million people developed TB in 2013, and 1.5 million died, including 360 000 people who were living with HIV.
The Global Tuberculosis Report 2014 highlights that while the number of TB deaths among people living with HIV has been falling for almost a decade—from 540 000 in 2004 to 360 000 in 2013—early case detection, antiretroviral treatment, preventive therapy and other key activities need to be further scaled-up.
Keywords: HIV, tuberculosis (TB), financing, women, children, deaths
Tuberculosis (TB) drug resistance surveillance has been a pathfinder in global efforts against antimicrobial resistance (AMR).
20 years: it is the oldest and largest AMR surveillance project in the world.
Globally, the proportion of new cases with Multidrug-resistant TB (MDR-TB) has not changed in recent years. However, almost half a million new cases continue to emerge each year and serious epidemics in some countries jeopardize progress.
There is progress in the MDR-TB response: 136 000 cases eligible MDR-TB treatment were detected in 2013, up from 52 825 cases detected in 2009. The number of MDR-TB cases enrolled on treatment went up from 30 500 in 2009 to 97 000 in 2013.
Key challenges in the MDR-TB response include: growing gaps between numbers detected and numbers started on treatment, poor treatment outcomes due to health system weaknesses and inadequate drug regimens, and insufficient funding including for research.
5 priority actions are urgently needed to address the global MDR-TB crisis.
UNITAID was launched in 2006 at the United Nations General Assembly by the governments of Brazil, Chile, France, Norway and the United Kingdom to improve access to vital medicines, tests and prevention products for people living with HIV/AIDS, TB and malaria in low income countries. Its pioneering investments, financed significantly by an air ticket levy, have shaped the markets for paediatric and second line medicines for HIV/AIDS, new diagnostic tools to detect TB and the provision of ACTs to private sector outlets where up to 60% of people seek treatment for malaria in high burden countries. Reflecting on these accomplishments and looking to address gaps in the availability and affordability of life-saving products for the three diseases, UNITAID produced a new strategy for 2013-2016.
Keywords: HIV/AIDS, TB, malaria, medicines, diagnostics, paediatric, treatment
UNITAID’s Strategy 2013-2016 guides the organization’s response to HIV/AIDS, malaria and TB. In total, these global epidemics kill almost 4 million people every year. Forward looking and flexible, UNITAID collects intelligence on product markets for these diseases in order to inform its investments, which are implemented by the world’s top development organizations.
Keywords: HIV/AIDS, TB, malaria, medicines, diagnostics, prevention
TB is the leading cause of death among people living with HIV (PLHIV). One in five HIV-related deaths is caused by TB. Untreated TB in people with HIV can lead to death in weeks.
Keywords: TB, HIV, co-infection, treatment, discrimination, health care
The purpose of UNITAID is to contribute to the achievement of global long-term goals for HIV, tuberculosis and malaria through its interventions in product markets. These goals have determined the Strategic Objectives described in this Strategy for the coming four years and are shared by the international community at large.
Keywords: HIV/AIDS, TB, malaria, medicines, funding, diagnostics, prevention
AZD5847 belongs to the oxazolidinone class of compounds, which function as protein synthesis inhibitors and were first discovered in the mid- 1980s. Linezolid was the first compound of the oxazolidinone class to be approved for marketing and is most commonly used to treat drug-resistant TB. However, the use of linezolid has been limited by toxicity concerns, particularly haematological effects after periods of treatment over 14 days.
AZD5847 (previously referred to as AZD2563, generic name posizolid) is a modified analogue of the linezolid compound. AZD5847 was originally designed for treatment of gram-positive infections but was subsequently repurposed as an anti-TB agent. Like linezolid, AZD5847 has a bactericidal effect against mycobacterium TB in macrophages as well as in murine models of acute and chronic TB infection.
The patent landscape in Annex I of this report sets out the key patents and patent applications for bedaquiline, including their geographical patent coverage, as of June 2011. While every effort has been made to obtain comprehensive and accurate information on the status and geographical scope of the patents covering bedaquiline, in many countries patent information is not readily available to the public or not updated on a regular basis. In addition, some patent applications may have been published only after the searches were conducted. As such, there may be other relevant patents which have subsequently been published and which are not included in this landscape. Accordingly, the information provided herein is subject to the above disclaimers.
Keywords: HIV, TB, drugs, treatment, coverage
This is the eighteenth global report on tuberculosis (TB) published by WHO in a series that started in 1997. It provides a comprehensive and up-to-date assessment of the TB epidemic and progress in implementing and ﬁnancing TB prevention, care and control at global, regional and country levels using data reported by 197 countries and territories that account for over 99% of the world’s TB cases.
Just over two years remain before the end of 2015, the target deadline. This special supplement of the Global Tuberculosis Report 2013 summarizes the status of progress towards targets set within the MDG framework and for the response to TB/HIV and MDR-TB specifically (Table S2), and the actions needed to either move beyond or accelerate towards these targets. Snapshots are provided globally, regionally and for the 22 high-burden countries (HBCs) that have about 80% of the world’s TB cases (Figure S1) and that have received the greatest attention at the global level since 2000.